Pleconaril

Drug Profile

Pleconaril

Alternative Names: Picovir; VP 63843; WIN 63843

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Antivirus Therapeutics; Merck & Co; ViroPharma
  • Class Antivirals; Oxadiazoles; Small molecules
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Enterovirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Enterovirus infections
  • Discontinued Common cold; Picornavirus infections

Most Recent Events

  • 03 Dec 2004 Schering-Plough's agreement with ViroPharma to license intranasal pleconaril for treatment of the common cold in the US and Canada became effective upon early termination of the Hart-Scott-Rodino Antitrust Improvement Act
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 25 Aug 2004 Schering-Plough has exercised its option to license the intranasal formulation of pleconaril for the treatment of the common cold in the US and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top